Gosset D, Mizon C, Savinel P, Balduyck M, Boniface B, Hatron P Y, Mizon J, Devulder B
Clinique médicale A, Service de Médecine interne, CHU, Lille.
Presse Med. 1988 Feb 27;17(7):329-32.
Urinary trypsin inhibitory capacity is mainly due to the excretion of a glycoprotein which is immunologically related to the inter alpha-trypsin inhibitor and may be a proteolytic degradation product of that substance. It was tested in 133 subjects divided into 7 groups: 24 healthy controls (group A), 21 patients with bacterial infection (group B), 37 with bacterial infection under antibiotic therapy (group C), 25 with connective tissue disease (group D), 8 with infected connective tissue disease (group E), 14 with cancer (group F) and 4 with infected cancer (group G). Urinary trypsin inhibitory capacity level was very low in controls (3.32 +/- 0.8 U/g urinary creatinine), but it was dramatically increased when infection was present (149.67 +/- 23.6 U/g urinary creatinine). This test appeared to be more effective than serum C-protein measurement simultaneous carried out in the same patients. Urinary trypsin inhibitory capacity is not related to the degree of proteinuria in the urine sample, but it is increased in patients with chronic renal failure excluded from this study. Thus, its measurement is a sensitive, easy and useful test for detecting and monitoring infections. The return to its physiological value is a very good argument in favour of therapeutic effectiveness.
尿胰蛋白酶抑制能力主要归因于一种糖蛋白的排泄,该糖蛋白与α-间胰蛋白酶抑制剂存在免疫相关性,可能是该物质的蛋白水解降解产物。对133名受试者进行了测试,他们被分为7组:24名健康对照者(A组)、21名细菌感染患者(B组)、37名接受抗生素治疗的细菌感染患者(C组)、25名结缔组织病患者(D组)、8名感染性结缔组织病患者(E组)、14名癌症患者(F组)和4名感染性癌症患者(G组)。对照组的尿胰蛋白酶抑制能力水平非常低(3.32±0.8 U/g尿肌酐),但当存在感染时,该水平显著升高(149.67±23.6 U/g尿肌酐)。该检测似乎比在同一患者中同时进行的血清C蛋白测量更有效。尿胰蛋白酶抑制能力与尿样中的蛋白尿程度无关,但在本研究排除的慢性肾衰竭患者中升高。因此,其测量是检测和监测感染的一种敏感、简便且有用的检测方法。其恢复到生理值是支持治疗有效性的一个很好的依据。